AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12352219 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 21
Study 10629385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroepiandrosterone (50 mg/day)
Number of subjects: 50
Study 10629385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10150537 — intervention group
Group type: EXPERIMENTAL
Intervention: HRA report with counseling
Number of subjects: 161
Study 10150537 — intervention group
Group type: COMPARATOR
Intervention: No HRA report or counseling (Control)
Number of subjects: 161
Study 2178719 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheet containing Ofloxacin
Number of subjects: 20
Study 2178719 — intervention group
Group type: COMPARATOR
Intervention: Collagen sheet
Number of subjects: 20
Study 2178719 — intervention group
Group type: COMPARATOR
Intervention: Ointment-impregnated gauze
Number of subjects: 20
Study 7378115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation A (hydrous solution, 1 mg F−/100 ml)
Number of subjects: 12
Study 7378115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation B (2 tablets at 0.5 mg F−)
Number of subjects: 12
Study 7378115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation C (1 NaF tablet with 1 mg F−)
Number of subjects: 12
Study 7378115 — intervention group
Group type: COMPARATOR
Intervention: All preparations
Number of subjects: 12
Study 6415745 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 10
Study 6415745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28690028 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) with or without intravenous immunoglobulin (IVIG)
Number of subjects: 71
Study 28690028 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) with or without intravenous immunoglobulin (IVIG)
Number of subjects: 71
Study 28690028 — intervention group
Group type: EXPERIMENTAL
Intervention: MEPM or PIPC/TAZ
Number of subjects: 71
Study 28690028 — intervention group
Group type: EXPERIMENTAL
Intervention: MEPM + IVIG or PIPC/TAZ + IVIG
Number of subjects: 71
Study 27315546 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT (bevacizumab, trastuzumab, and paclitaxel)
Number of subjects: 84
Study 27315546 — intervention group
Group type: COMPARATOR
Intervention: HA-HAT (trastuzumab and bevacizumab with paclitaxel after progression)
Number of subjects: 84
Study 27315546 — intervention group
Group type: COMPARATOR
Intervention: HA-HAT (trastuzumab and bevacizumab)
Number of subjects: 84
Study 27315546 — intervention group
Group type: COMPARATOR
Intervention: HA-HAT (bevacizumab and paclitaxel)
Number of subjects: 84
Study 24942239 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% sucrose solution
Number of subjects: 537
Study 24942239 — intervention group
Group type: COMPARATOR
Intervention: 25% sucrose solution
Number of subjects: 537
Study 24942239 — intervention group
Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 537
Study 22893496 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block (Anesthesia group; n=120)
Number of subjects: 241
Study 22893496 — intervention group
Group type: COMPARATOR
Intervention: No anesthesia (Control group; n=121)
Number of subjects: 241
Study 20549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and carboplatin (TC) for 4 cycles every 3 weeks
Number of subjects: 74
Study 20549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and carboplatin (TC) for 4 cycles every 3 weeks + trastuzumab for HER2-positive tumors
Number of subjects: 74
Study 20549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving a pathologic complete response (pCR)
Number of subjects: 74
Study 20549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving a clinical complete response (cCR)
Number of subjects: 74
Study 20549829 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and recurrence-free survival (RFS) rates
Number of subjects: 74
Study 18942601 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide / oxygen analgesia (NOA) with fasting
Number of subjects: 113
Study 18942601 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide / oxygen analgesia (NOA) without fasting
Number of subjects: 113
Study 16155261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stearic acid diet
Number of subjects: 45
Study 16155261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic acid diet
Number of subjects: 45
Study 16155261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-linoleic acid diet
Number of subjects: 45
Study 12812212 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-slice/helical computed tomography (CT)
Number of subjects: 0
Study 12812212 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 0
Study 12812212 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-slice/helical CT
Number of subjects: 0
Study 11044476 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA IgG1 positivity in sera and a villous height/crypt depth ratio <3:1 as index of intestinal atrophy
Number of subjects: 30
Study 11044476 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 8-10 months
Number of subjects: 30
Study 11044476 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 children with gastroenterological diseases other than CD and 63 healthy children)
Number of subjects: 30
Study 8974104 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.15 mg.kg‐1.d‐1)
Number of subjects: 20
Study 1334821 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (lipid-lowering agent)
Number of subjects: 151
Study 1334821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 6145290 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 36
Study 6145290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30277921 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (28 minutes of high-intensity exercises > 80% of maximum heart rate, 3 times a week for 12 weeks)
Number of subjects: 26
Study 30277921 — intervention group
Group type: COMPARATOR
Intervention: Combined training (60 minutes of walking at 70% of maximum heart rate and resistance exercises at 70% of one repetition maximum, 3 times a week for 12 weeks)
Number of subjects: 26
Study 29486426 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher's evaluation findings
Number of subjects: 0
Study 29486426 — intervention group
Group type: COMPARATOR
Intervention: Program staff's evaluation findings
Number of subjects: 0
Study 27694216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate-rich beetroot juice (BR), 6.2 mmol of NO3- per shot, seven 70-ml shots consumed during the 48 hours after blood donation.
Number of subjects: 22
Study 27694216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL), seven 70-ml shots consumed during the 48 hours after blood donation.
Number of subjects: 22
Study 27694216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate-rich beetroot juice (BR)
Number of subjects: 22
Study 27694216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study 25364300 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich liquid drinks (CRLDs)
Number of subjects: 142
Study 25364300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 25364300 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 21678140 — intervention group
Group type: EXPERIMENTAL
Intervention: MO(250) (moderate intensity, 2 × 6 × 250 m/rec 30 s/5 min at 85% of V(max))
Number of subjects: 13
Study 21678140 — intervention group
Group type: EXPERIMENTAL
Intervention: MO(500) (2 × 3 × 500 m/rec 1 min/5 min at 85% V(max))
Number of subjects: 13
Study 21678140 — intervention group
Group type: EXPERIMENTAL
Intervention: HI(250) (high intensity, 2 × 6 × 250 m/rec 30 s/5 min at 105% V(max))
Number of subjects: 13
Study 20953528 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg intravenous)
Number of subjects: 90
Study 20953528 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Sevoflurane in 60% nitrous oxide and 40% oxygen with tidal-volume-breath (TVB)
Number of subjects: 90
Study 20953528 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Sevoflurane in 60% nitrous oxide and 40% oxygen with tidal-volume-breath (TVB)
Number of subjects: 90
Study 20953528 — intervention group
Group type: COMPARATOR
Intervention: Control (before alfentanil)
Number of subjects: 90
Study 18806686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET (175 microg/275 microg)
Number of subjects: 82
Study 18806686 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NET acetate (1 mg/0.5 mg)
Number of subjects: 82
Study 15983301 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and rosiglitazone 4 mg twice daily
Number of subjects: 50
Study 15983301 — intervention group
Group type: COMPARATOR
Intervention: Insulin and placebo
Number of subjects: 50
Study 15983301 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and rosiglitazone
Number of subjects: 50
Study 14613469 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide-metformin tablets
Number of subjects: 72
Study 14613469 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea plus metformin (SU+Met)
Number of subjects: 72
Study 10877192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate (FDP) infusion (5 g, 10%)
Number of subjects: 45
Study 10877192 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion (5 g)
Number of subjects: 45
Study 8855984 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron combined with dexamethasone
Number of subjects: 101
Study 8855984 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101
Study 8855984 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron only for 5 days after chemotherapy
Number of subjects: 101
Study 8855984 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-emetic treatment with dexamethasone
Number of subjects: 101
Study 8855984 — intervention group
Group type: EXPERIMENTAL
Intervention: minimal tumour burden
Number of subjects: 101
Study 8855984 — intervention group
Group type: EXPERIMENTAL
Intervention: low neuroticism
Number of subjects: 101
Study 8855984 — intervention group
Group type: EXPERIMENTAL
Intervention: no history of motion sickness
Number of subjects: 101
Study 1815521 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone 25 mg orally
Number of subjects: 12
Study 1815521 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroximone 50 mg orally
Number of subjects: 12
Study 1815521 — intervention group
Group type: COMPARATOR
Intervention: Piroximone intravenously
Number of subjects: 12
Study 6869204 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 5 mg once daily for 14 days
Number of subjects: 6
Study 6869204 — intervention group
Group type: COMPARATOR
Intervention: Control period (placebo)
Number of subjects: 6
Study 6869204 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide treatment
Number of subjects: 6
Study 29746301 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) early infant HIV testing
Number of subjects: 277
Study 29746301 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) infant HIV testing
Number of subjects: 277
Study 26474810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg twice daily
Number of subjects: 2651
Study 26474810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2651
Study 25757171 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Listab) 75 mg/day
Number of subjects: 60
Study 25757171 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 60
Study 25757171 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) or VKA
Number of subjects: 60
Study 25757171 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (Listab)
Number of subjects: 60
Study 22972862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior active tuberculosis
Number of subjects: 979
Study 22972862 — intervention group
Group type: COMPARATOR
Intervention: No prior active tuberculosis
Number of subjects: 979
Study 20583949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutogliptin 400 mg once daily for 5 days
Number of subjects: 0
Study 20583949 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily for 5 days
Number of subjects: 0
Study 20583949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutogliptin 400 mg once daily and Metformin 1000 mg twice daily for 5 days
Number of subjects: 0
Study 19047703 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing (using sensory nerve conduction velocity) with stringent criteria
Number of subjects: 143
Study 19047703 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing (using sensory nerve conduction velocity) with lax criteria
Number of subjects: 143
Study 19047703 — intervention group
Group type: COMPARATOR
Intervention: Pretest probability assessment using CTS-6
Number of subjects: 143
Study 15919161 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy relapse prevention treatment
Number of subjects: 141
Study 15919161 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 141
Study 15919161 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous cessation
Number of subjects: 141
Study 12527674 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 230
Study 11149105 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate (Ferrlecit)
Number of subjects: 13
Study 8898763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension defined as systolic blood pressure ≥ 140 mmHg or diastolic pressure ≥ 90 mmHg or current use of antihypertensive medications
Number of subjects: 1004
Study 8898763 — intervention group
Group type: COMPARATOR
Intervention: Comparison with NHANES III
Number of subjects: 1004
Study 8898763 — intervention group
Group type: COMPARATOR
Intervention: Comparison with San Antonio Mexican Americans
Number of subjects: 1004
Study 1892962 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam treatment
Number of subjects: 36
Study 1892962 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study 1892962 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders to alprazolam
Number of subjects: 36
Study 1892962 — intervention group
Group type: COMPARATOR
Intervention: Patients clinically unchanged with placebo
Number of subjects: 36
Study 6325994 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol, 320 or 960 mg/day
Number of subjects: 10
Study 6325994 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 30476104 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL-PLEX (organic forms of Se, OSe)
Number of subjects: 24
Study 30476104 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 blend of ISe and OSe (MIX)
Number of subjects: 24
Study 30476104 — intervention group
Group type: COMPARATOR
Intervention: Sodium selenite (inorganic Se, ISe)
Number of subjects: 24
Study 29954199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 240
Study 29954199 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA (all-polyethylene and modular metal-backed)
Number of subjects: 240
Study 26230332 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of lopinavir and amprenavir
Number of subjects: 0
Study 26230332 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir alone
Number of subjects: 0
Study 26230332 — intervention group
Group type: COMPARATOR
Intervention: Amprenavir alone
Number of subjects: 0
Study 22840353 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 120
Study 22840353 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing techniques in RARP
Number of subjects: 120
Study 22840353 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical prostatectomy (LRP)
Number of subjects: 120
Study 21857481 — intervention group
Group type: EXPERIMENTAL
Intervention: LC/LERV (N=45)
Number of subjects: 98
Study 21857481 — intervention group
Group type: COMPARATOR
Intervention: LC/IOES (N=53)
Number of subjects: 98
Study 19792989 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 or 25 mg/day for 9 weeks
Number of subjects: 202
Study 17719559 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention focusing
Number of subjects: 63
Study 17719559 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 63
Study 15475095 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of more than 3 l of crystalloids during abdominal surgery
Number of subjects: 150
Study 15475095 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of more than 500 ml of colloids during abdominal surgery
Number of subjects: 150
Study 15475095 — intervention group
Group type: COMPARATOR
Intervention: Other studied factors
Number of subjects: 150
Study 11345374 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-by-side method
Number of subjects: 219
Study 11345374 — intervention group
Group type: COMPARATOR
Intervention: Serial method
Number of subjects: 219
Study 9605678 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography guidance
Number of subjects: 286
Study 9605678 — intervention group
Group type: COMPARATOR
Intervention: Standard method
Number of subjects: 286
Study 7742331 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine 10 micrograms
Number of subjects: 100
Study 7742331 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine 20 micrograms
Number of subjects: 100
Study 1965288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (A.D.A.-accepted)
Number of subjects: 0
Study 1965288 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrices containing anticalculus agents (soluble pyrophosphates, zinc chloride, zinc oxide)
Number of subjects: 0
Study 97033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen taken orally for 3 days
Number of subjects: 10
Study 97033 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg DSCG inhaled four times daily for 3 days
Number of subjects: 10
Study 97033 — intervention group
Group type: EXPERIMENTAL
Intervention: ketotifen
Number of subjects: 10
Study 97033 — intervention group
Group type: EXPERIMENTAL
Intervention: DSCG
Number of subjects: 10
Study 31822848 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomics ADvISER decision aid
Number of subjects: 133
Study 28926349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care program plus routine hospital care
Number of subjects: 0
Study 28926349 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 0
Study 26436433 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Thai Massage (TTM)
Number of subjects: 29
Study 26436433 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 29
Study 22956679 — intervention group
Group type: EXPERIMENTAL
Intervention: intervention group (self-regulation)
Number of subjects: 851
Study 22956679 — intervention group
Group type: COMPARATOR
Intervention: standard group (intention formation)
Number of subjects: 851
Study 21613310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (0.01-10.0 mg/kg)
Number of subjects: 32
Study 21613310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (1.0 and 3.0 mg/kg)
Number of subjects: 32
Study 21613310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab (n=15 with baseline DAS28 >3.2)
Number of subjects: 32
Study 21613310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 20394133 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Contracting (Group 3)
Number of subjects: 27
Study 20394133 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Contracting (Group 4)
Number of subjects: 27
Study 20394133 — intervention group
Group type: COMPARATOR
Intervention: Control Group 1
Number of subjects: 27
Study 20394133 — intervention group
Group type: COMPARATOR
Intervention: Control Group 2
Number of subjects: 27
Study 16958291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE + One Step Plus applied according to manufacturer's recommendation (2 coats of adhesive)
Number of subjects: 29
Study 16958291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE + One Step Plus (4 coats of adhesive)
Number of subjects: 29
Study 16958291 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid + One Step Plus applied according to manufacturer's recommendation (2 coats of adhesive)
Number of subjects: 29
Study 16958291 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid + One Step Plus (4 coats of adhesive)
Number of subjects: 29
Study 16958291 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 29
Study 15193480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of l-carnitine (2 g/d) and l-acetyl-carnitine (1 g/d)
Number of subjects: 60
Study 15193480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10958260 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine, clomipramine, paroxetine)
Number of subjects: 326
Study 9373765 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 infusion (0.4 pmol kg-1 min-1)
Number of subjects: 12
Study 9373765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1373485 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr-strontium chloride (0 MBq, n=21; 37 MBq, n=65; 75 MBq, n=72; 100 MBq, n=25; 150 MBq, n=17)
Number of subjects: 200
Study 1373485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 1373485 — intervention group
Group type: EXPERIMENTAL
Intervention: 89Sr-strontium chloride
Number of subjects: 200
Study 4076305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 2.5 mg
Number of subjects: 0
Study 4076305 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 0